Shares of UnitedHealth Group Incorporated (NYSE:UNH) dropped more than 2% on Monday following news that Berkshire Hathaway had exited its investment in the healthcare company.
The decline came after Berkshire Hathaway, led by CEO Greg Abel, revealed it sold its entire stake in UnitedHealth as part of a first-quarter portfolio reshuffle.
Berkshire's Brief Bet on UnitedHealth
Berkshire Hathaway first disclosed its investment in UnitedHealth last August, when it purchased 5 million shares.
At the time, the move boosted investor confidence, with many viewing it as a vote of confidence in the company's turnaround efforts under CEO Stephen Hemsley.
However, on May 15, Berkshire confirmed it had exited its position entirely, ending a holding that lasted less than a year.
Analyst Remains Neutral Despite Bullish Tone
Separately, on May 13, Bank of America analyst Kevin Fischbeck raised his price recommendation on UNH to $420 from $380.
Fischbeck reiterated a Neutral rating on the shares, noting that conversations with UnitedHealth's leadership team at the BofA Healthcare Conference carried a "bullish" tone.
Management indicated it believes the company can return to at least the low end of its target margins across most of its businesses by 2028.
UnitedHealth Group operates across several healthcare and wellness businesses, including Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare.
Its insurance operations span employer and individual plans, Medicare and retirement services, and community and state programs.
The stock drop reflects market reaction to Berkshire's exit, though the broader outlook for UnitedHealth remains tied to its ability to meet margin targets and navigate the healthcare landscape.
